Compare iShares MBS ETF (MBB) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs BIO-TECHNE Corp — how do they compare? iShares MBS ETF trades at $89.7 (market cap $35.41B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: iShares MBS ETF is far larger — about 3.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and BIO-TECHNE Corp for 63 Days on average.
| MBB | TECH | |
|---|---|---|
Market Cap | $35.41B | $11.36B |
Volume | 5,388,525 | 5,390,331 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $72.61 |
52-Week Low | $89.09 | $43.31 |
Typical Hold Time | 96 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.
The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
